Project Execution Plan: Calibrating a Causal Transformer with Aggregate RCT Data

MyWay Digital Health

June 8, 2025

Abstract

This document outlines the step-by-step instructions for implementing the Causal Transformer calibration project. The objective is to develop a system that produces personalized treatment effect estimates that are calibrated against aggregate evidence from published Randomized Controlled Trials (RCTs). The methodology combines a Causal Transformer as a base predictor with a Gaussian Process (GP) as a calibration model. This revision incorporates the use of a dedicated Synthetic Data Generation (SDG) model for creating patient cohorts.

1 Phase 1: Base Model Preparation and Training

The first phase involves defining the data structure, preparing the observational dataset from SCI-Diabetes, and training the base Causal Transformer model.

1.1 Understanding the Causal Transformer Architecture

The Causal Transformer is a sequence model adapted for causal inference. It processes patient data as a series of temporal "tokens". For our purposes, we will model a simplified, static version where each patient has three corresponding input streams:

- Covariate Stream (X): A vector of baseline patient characteristics (e.g., age, sex, comorbidities, baseline biomarkers). $\mathbf{X} \in \mathbb{R}^{d_x}$.
- Treatment Stream (A): A vector indicating the treatment(s) assigned. This will be one-hot encoded. $\mathbf{A} \in \mathbb{R}^{d_a}$.
- Outcome Stream (Y): A vector of the outcomes observed for the patient under treatment \mathbf{A} , $\mathbf{Y} \in \mathbb{R}^{d_y}$.

The model is trained to predict the outcome stream \mathbf{Y} given the history of covariates \mathbf{X} and treatments \mathbf{A} . It can then be used to generate counterfactual predictions by changing the input treatment vector \mathbf{A} .

1.2 Step 1.1: Define Data Streams (A, X, Y)

We will define the specific variables for each stream.

• Treatments (A): Based on our target RCTs, we will initially focus on SGLT2 inhibitors and GLP-1 receptor agonists. The vector A should encode treatment type and potentially dose level, e.g., [SGLT2i_low, SGLT2i_high, GLP1a_low, GLP1a_high, Placebo].

- Outcomes (Y): The outcome vector Y should contain outcomes that are both clinically important and commonly reported in our set of RCTs. A task is to survey all N=25 RCTs and identify the set of common primary and key secondary outcomes. A proposed initial set is:
 - Change in HbA_{1c} from baseline.
 - Time-to-first Major Adverse Cardiovascular Event (MACE).
 - All-cause mortality.
- Covariates (X): See next step.

1.3 Step 1.2: Covariate Selection (The X vector)

This is a critical data curation task. The set of covariates **X** must be features that are available in **both** the SCI-Diabetes observational dataset and reported as baseline characteristics in our N=25 grounding RCTs.

- 1. Create a master spreadsheet of all baseline characteristics reported in the "Table 1" of each of the 25 RCTs.
- 2. Create a list of all available, high-quality features in the SCI-Diabetes dataset.
- 3. The final covariate vector **X** will be the **intersection of these two sets**. This ensures that we can fully describe each RCT population using features the Transformer understands.

Note: For simplicity and robustness, it is advisable to start with a parsimonious set of universally available covariates (e.g., age, sex, BMI, baseline HbA1c, baseline eGFR, duration of diabetes, history of cardiovascular disease) and expand later if necessary.

1.4 Step 1.3: Create the Master Dataset

With A, X, and Y defined, extract the relevant data from the SCI-Diabetes database.

- 1. For each patient in SCI-Diabetes, create a record containing their baseline covariate vector **X**, the treatment they received **A**, and the outcomes they experienced **Y**.
- 2. Perform necessary cleaning, imputation (e.g., MICE), and normalization (e.g., standard scaling for continuous features).
- 3. The final output should be a single, clean dataset (e.g., a .csv or .parquet file) ready for model training.

1.5 Step 1.4: Train the Causal Transformer

- 1. Download a public implementation of the Causal Transformer (e.g., from the original authors' GitHub repository).
- 2. Adapt the data loader to read our master dataset format.
- 3. Configure the model architecture and training hyperparameters.
- 4. Train the Causal Transformer model on the entire SCI-Diabetes dataset. This is a one-time, computationally intensive step.
- 5. Save the trained model weights. This is now your **Base Predictor**.

2 Phase 2: Calibration Model Development

This phase involves using the Base Predictor to generate predictions for our RCTs and preparing the data to train the calibration model.

2.1 Step 2.1: Simulate RCT Cohorts

For each of the $i \in \{1, ..., 25\}$ RCTs:

- 1. Generate a large synthetic patient pool: Utilize the project's dedicated synthetic data generation models to produce a large pool of virtual patients ($M \approx 1,000,000$). Each patient j must have a complete covariate vector \mathbf{X}_j that is statistically representative of the SCI-Diabetes population.
- 2. **Apply Exclusion Criteria:** Apply the pragmatic filters identified in the project planning phase (e.g., age range, baseline values) to this pool to create a candidate set of patients.
- 3. Match Population Characteristics via Weighting: To avoid the curse of dimensionality, use a weighting technique like Iterative Proportional Fitting (Raking) to assign a weight w_j to each patient in the candidate set. Adjust the weights w_j such that the weighted summary statistics of the synthetic cohort match the target statistics from the RCT's Table 1.

$$\begin{split} \sum_{j=1}^{M'} w_j \cdot \text{age}_j &= \text{mean_age}_{\text{RCT}_i} \\ \sum_{j=1}^{M'} w_j \cdot \text{is_male}_j &= \text{proportion_male}_{\text{RCT}_i} \\ &: \end{split}$$

The result is a weighted set of virtual patients that statistically replicates the population of RCT_i .

2.2 Step 2.2: Generate Transformer Predictions

For each simulated, weighted RCT cohort i:

- 1. Feed the cohort's covariate vectors **X** through the Base Predictor twice:
 - ullet Once with the treatment vector $\mathbf{A}_{\text{treat}}$ to get predicted outcomes $\hat{\mathbf{Y}}_{\text{treat}}$.
 - Once with the treatment vector $\mathbf{A}_{\text{placebo}}$ to get predicted outcomes $\hat{\mathbf{Y}}_{\text{placebo}}$.
- 2. Calculate the Individual Treatment Effect (ITE) for each patient j: ITE $_j = \hat{\mathbf{Y}}_{\text{treat},j} \hat{\mathbf{Y}}_{\text{placebo},j}$.
- 3. Calculate the Transformer's predicted Average Treatment Effect (ATE) for that cohort by taking the weighted average of the ITEs:

$$ATE_{transformer,i} = \sum_{j=1}^{M'} w_j \cdot ITE_j$$
 (1)

2.3 Step 2.3: Feature Engineering & Error Calculation

For each RCT i:

1. **Compute** Population_Vector_i: This is the vector of summary statistics from the RCT's Table 1 that you used as targets for raking. It is your feature vector for the calibration model.

$$\texttt{Population_Vector}_i = [\text{mean_age}, \text{sd_age}, \text{prop_male}, \dots]$$

2. Calculate Target $Error_i$: This is the target variable for the calibration model. Let $ATE_{rct,i}$ be the true ATE reported in the publication for RCT i.

$$Error_i = ATE_{transformer,i} - ATE_{rct,i}$$
 (2)

You will have one such error value for each outcome (e.g., Error_HbA1c, Error_MACE). You will train a separate GP for each outcome.

3 Phase 3: Analysis and Calibration Model Training

3.1 Step 3.1: Visualize the Manifold Hypothesis (t-SNE)

To build intuition and visually validate our core hypothesis, we will visualize the error manifold.

- 1. Take the set of all N = 25 Population_Vectors you created. This is a dataset where each row is an RCT, and columns are population characteristics.
- 2. Use a dimensionality reduction algorithm, such as t-SNE or UMAP, to project these high-dimensional vectors into a 2D space.
- 3. Create a scatter plot of the 2D-projected points.
- 4. Color each point on the plot by its corresponding $Error_i$ value. Use a continuous color scale (e.g., blue for negative error, red for positive error).
- 5. **Interpretation:** If the manifold hypothesis holds, this plot will show structure. You should see "blobs" or gradients of color, indicating that RCTs with similar populations (and are therefore close in the t-SNE plot) also have similar prediction errors. A random-looking "salt and pepper" plot would invalidate the hypothesis.

3.2 Step 3.2: Train the GP Calibration Model

- 1. Create the training dataset for the GP:
 - Input Features: The N=25 Population_Vectors.
 - Target Variable: The N=25 Error values.
- 2. Using a library like GPyTorch, scikit-learn, or GPflow, train a Gaussian Process Regressor. The GP will learn the function:

$$\operatorname{GP}(\operatorname{\texttt{Population_Vector}}) o (\mu_{\operatorname{error}}, \sigma^2_{\operatorname{error}})$$

3. Choose a suitable kernel, such as the RBF (Radial Basis Function) kernel, and optimize its hyperparameters (e.g., lengthscale, variance) by maximizing the log marginal likelihood on the training data.

4 Phase 4: Deployment for Calibrated Prediction

This is the final workflow for predicting the outcome of a new target population (e.g., a new trial that is underway).

- 1. **Define Target Population:** Obtain the baseline characteristics (the "Table 1") for the new target population. This forms your new Population_Vector_new.
- 2. Generate Raw ATE: Simulate a cohort matching Population_Vector_new (using the same SDG model and raking procedure) and run it through the Base Predictor (the Causal Transformer) to get the raw prediction, ATE_raw.
- 3. Predict Error: Feed Population_Vector_new into the trained GP Calibration Model. It will output the predicted error mean $(\delta_{\text{predicted}})$ and variance (σ_{δ}^2) .
- 4. Calculate Final Estimate: Combine the outputs to get the final calibrated ATE and its 95% confidence interval.

$$ATE_calibrated = ATE_raw - \delta_{predicted}$$
 (3)

$$95\%~{\rm CI} = {\tt ATE_calibrated} \pm 1.96 \cdot \sqrt{\sigma_\delta^2} \eqno(4)$$

This provides a final, trustworthy prediction that is consistent with the body of existing clinical trial evidence, complete with a principled uncertainty estimate.